AJMC®: How is COPD definitively diagnosed in clinical practice, and how does this disease create a clinical burden on patients and caregivers? Dr Rali: COPD diagnosis requires both clinical context ...
Editor’s note: This is an automatically generated transcript, which has been slightly edited for clarity. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.
Add Yahoo as a preferred source to see more of our stories on Google. Woman’s World has affiliate partnerships. We receive compensation when you click on a link and make a purchase. Learn more! Sure, ...
Chronic obstructive pulmonary disease (COPD) makes it hard to breathe. Narrowed airways can make you cough, wheeze, and feel short of breath. It can affect how you exercise, work, and do other daily ...
After years of limited advancements in chronic obstructive pulmonary disease (COPD) treatment, patients now have new options. Regeneron Pharmaceuticals Inc (NASDAQ:REGN) and Sanofi SA’s (NASDAQ:SNY) ...
We live longer and longer, and as we age, a lot of us develop a series of health issues and chronic diseases, including Chronic Obstructive Pulmonary Disease (COPD), which is found in around 600 ...
Among patients with blood eosinophil counts greater than or equal to 150 cells/µL, the reduction in the annual rate of moderate to severe COPD exacerbations was found to be nominally significant. The ...
Hosted on MSN
FDA Approves Mepolizumab for COPD
The FDA approved mepolizumab (Nucala) for adults with inadequately controlled chronic obstructive pulmonary disease (COPD), drugmaker GSK announced on Thursday. Labeling for the interleukin-5 (IL-5) ...
AJMC®: What recent developments in the therapeutic landscape of chronic obstructive pulmonary disease (COPD) do you think have the greatest potential to shift how treatment is managed? Dr Martinez: ...
Boehringer Ingelheim Pharmaceuticals, Inc. announced today that STIOLTO™ RESPIMAT ® (tiotropium bromide and olodaterol) Inhalation Spray is now available by prescription at pharmacies across the ...
Please provide your email address to receive an email when new articles are posted on . The FDA based mepolizumab’s approval on phase 3 MATINEE and METREX trial results. Mepolizumab has been assessed ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results